Becker's Healthcare December 4, 2024
CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively.
Under the Cell and Gene Therapy Access Model, CMS will tie payments for the therapies to their effectiveness in improving health outcomes for Medicaid recipients, according to a Dec. 4 news release from the...
Today's Sponsors
Today's Sponsor
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicaid, Payment Models, Pharma / Biotech, Value Based